148 related articles for article (PubMed ID: 31001934)
1. Predictive Factors for Efficacy of AST-120 Treatment in Diabetic Nephropathy: a Prospective Single-Arm, Open-Label, Multi-Center Study.
Hwang YC; Kim SW; Hur KY; Cha BS; Kim IJ; Park TS; Baik SH; Yoon KH; Lee KW; Lee IK; Lee MK
J Korean Med Sci; 2019 Apr; 34(15):e117. PubMed ID: 31001934
[TBL] [Abstract][Full Text] [Related]
2. Protective effect of an oral adsorbent on renal function in chronic renal failure: determinants of its efficacy in diabetic nephropathy.
Sanaka T; Akizawa T; Koide K; Koshikawa S
Ther Apher Dial; 2004 Jun; 8(3):232-40. PubMed ID: 15154877
[TBL] [Abstract][Full Text] [Related]
3. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects.
Konishi K; Nakano S; Tsuda S; Nakagawa A; Kigoshi T; Koya D
Diabetes Res Clin Pract; 2008 Sep; 81(3):310-5. PubMed ID: 18550198
[TBL] [Abstract][Full Text] [Related]
4. An oral adsorbent ameliorates renal overload of indoxyl sulfate and progression of renal failure in diabetic rats.
Aoyama I; Niwa T
Am J Kidney Dis; 2001 Jan; 37(1 Suppl 2):S7-S12. PubMed ID: 11158853
[TBL] [Abstract][Full Text] [Related]
5. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
6. Oral ADSORBENT AST-120 decreases carotid intima-media thickness and arterial stiffness in patients with chronic renal failure.
Nakamura T; Kawagoe Y; Matsuda T; Ueda Y; Shimada N; Ebihara I; Koide H
Kidney Blood Press Res; 2004; 27(2):121-6. PubMed ID: 15051932
[TBL] [Abstract][Full Text] [Related]
7. Effect of combined treatment of oral sorbent with protein-restricted diet on change of reciprocal creatinine slope in patients with CRF.
Sanaka T; Fujimoto K; Niwayama J; Nishimura H; Naito T; Higuchi C; Akizawa T; Koide K; Koshikawa S
Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S35-7. PubMed ID: 12612949
[TBL] [Abstract][Full Text] [Related]
8. Spherical carbon adsorbent (AST-120) protects deterioration of renal function in chronic kidney disease rats through inhibition of reactive oxygen species production from mitochondria and reduction of serum lipid peroxidation.
Owada S; Maeba T; Sugano Y; Hirayama A; Ueda A; Nagase S; Goto S; Nishijima F; Bannai K; Yamato H
Nephron Exp Nephrol; 2010; 115(4):e101-11. PubMed ID: 20424488
[TBL] [Abstract][Full Text] [Related]
9. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
Lewis EJ; Lewis JB
Clin Exp Nephrol; 2003 Mar; 7(1):1-8. PubMed ID: 14586737
[TBL] [Abstract][Full Text] [Related]
10. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
11. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.
Cha RH; Kang SW; Park CW; Cha DR; Na KY; Kim SG; Yoon SA; Han SY; Chang JH; Park SK; Lim CS; Kim YS
Clin J Am Soc Nephrol; 2016 Apr; 11(4):559-67. PubMed ID: 26912554
[TBL] [Abstract][Full Text] [Related]
12. Carbonic-adsorbent AST-120 reduces overload of indoxyl sulfate and the plasma level of TGF-beta1 in patients with chronic renal failure.
Iida S; Kohno K; Yoshimura J; Ueda S; Usui M; Miyazaki H; Nishida H; Tamaki K; Okuda S
Clin Exp Nephrol; 2006 Dec; 10(4):262-7. PubMed ID: 17186330
[TBL] [Abstract][Full Text] [Related]
13. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
[TBL] [Abstract][Full Text] [Related]
14. Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy.
Nakamura T; Sugaya T; Kawagoe Y; Ueda Y; Osada S; Koide H
Diabetes Care; 2005 Nov; 28(11):2728-32. PubMed ID: 16249547
[TBL] [Abstract][Full Text] [Related]
15. Tocotrienol-Rich Vitamin E from Palm Oil (Tocovid) and Its Effects in Diabetes and Diabetic Nephropathy: A Pilot Phase II Clinical Trial.
Tan SMQ; Chiew Y; Ahmad B; Kadir KA
Nutrients; 2018 Sep; 10(9):. PubMed ID: 30227659
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
[TBL] [Abstract][Full Text] [Related]
17. Effects of oral adsorbent AST-120 on the progression of chronic renal failure: a randomized controlled study.
Owada A; Nakao M; Koike J; Ujiie K; Tomita K; Shiigai T
Kidney Int Suppl; 1997 Dec; 63():S188-90. PubMed ID: 9407455
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of administering oral adsorbent AST-120 to patients with diabetes and advance-stage chronic kidney disease.
Hayashino Y; Fukuhara S; Akizawa T; Asano Y; Wakita T; Onishi Y; Kurokawa K;
Diabetes Res Clin Pract; 2010 Nov; 90(2):154-9. PubMed ID: 20708813
[TBL] [Abstract][Full Text] [Related]
19. Oral adsorbent AST-120 ameliorates interstitial fibrosis and transforming growth factor-beta(1) expression in spontaneously diabetic (OLETF) rats.
Aoyama I; Shimokata K; Niwa T
Am J Nephrol; 2000; 20(3):232-41. PubMed ID: 10878408
[TBL] [Abstract][Full Text] [Related]
20. Long-term effects of the oral adsorbent, AST-120, in patients with chronic renal failure.
Maeda K; Hamada C; Hayashi T; Shou I; Wakabayashi M; Fukui M; Horikoshi S; Tomino Y
J Int Med Res; 2009; 37(1):205-13. PubMed ID: 19215692
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
